Literature DB >> 20331662

Late-treated phenylketonuria and partial reversibility of intellectual impairment.

Scott D Grosse1.   

Abstract

Individuals with late-treated phenylketonuria (PKU) not detected by newborn screening but who followed dietary treatment for at least 12 months before 7 years of age have intelligence quotient (IQ) scores that range from severe impairment to the low-normal range. Among adults with late-treated PKU in California, 85% of those who were born from 1961 to 1978 had IQ scores of 70 or above. Longitudinal studies with repeated cognitive assessments often show average changes in cognitive test scores as high as 20-45 points. Although the severe cognitive impairment associated with untreated PKU can in many cases be partially reversed with dietary treatment, prompt initiation of treatment following newborn metabolic screening is essential for optimal development and the prevention of disability.

Entities:  

Mesh:

Year:  2010        PMID: 20331662     DOI: 10.1111/j.1467-8624.2009.01389.x

Source DB:  PubMed          Journal:  Child Dev        ISSN: 0009-3920


  8 in total

Review 1.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

2.  Decision analysis, economic evaluation, and newborn screening: challenges and opportunities.

Authors:  Lisa A Prosser; Scott D Grosse; Alex R Kemper; Beth A Tarini; James M Perrin
Journal:  Genet Med       Date:  2012-04-05       Impact factor: 8.822

Review 3.  Monetary Valuation of Children's Cognitive Outcomes in Economic Evaluations from a Societal Perspective: A Review.

Authors:  Scott D Grosse; Ying Zhou
Journal:  Children (Basel)       Date:  2021-04-29

Review 4.  Recommendations for the nutrition management of phenylalanine hydroxylase deficiency.

Authors:  Rani H Singh; Fran Rohr; Dianne Frazier; Amy Cunningham; Shideh Mofidi; Beth Ogata; Patricia L Splett; Kathryn Moseley; Kathleen Huntington; Phyllis B Acosta; Jerry Vockley; Sandra C Van Calcar
Journal:  Genet Med       Date:  2014-01-02       Impact factor: 8.822

5.  The Predictive Value of Genetic Analyses in the Diagnosis of Tetrahydrobiopterin (BH4)-Responsiveness in Chinese Phenylalanine Hydroxylase Deficiency Patients.

Authors:  Tianwen Zhu; Jun Ye; Lianshu Han; Wenjuan Qiu; Huiwen Zhang; Lili Liang; Xuefan Gu
Journal:  Sci Rep       Date:  2017-07-28       Impact factor: 4.379

6.  The effect of improved dietary control on cognitive and psychiatric functioning in adults with phenylketonuria: the ReDAPT study.

Authors:  Nicholas M Burgess; Wendy Kelso; Charles B Malpas; Toby Winton-Brown; Timothy Fazio; Julie Panetta; Gerard De Jong; Joanna Neath; Sonny Atherton; Dennis Velakoulis; Mark Walterfang
Journal:  Orphanet J Rare Dis       Date:  2021-01-18       Impact factor: 4.123

7.  Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis.

Authors:  Scott D Grosse
Journal:  Healthcare (Basel)       Date:  2015-11-11

8.  Newborn Screening and Treatment of Phenylketonuria: Projected Health Outcomes and Cost-Effectiveness.

Authors:  Huey-Fen Chen; Angela M Rose; Susan Waisbren; Ayesha Ahmad; Lisa A Prosser
Journal:  Children (Basel)       Date:  2021-05-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.